Treatment of chronic hepatitis C with interferon alfa-n3: A multicenter, randomized, open-label trial

Hepatology

Volumn 25, Issue 2, 1997, Pages 445-448

  Simon, Douglas M ^a,h   Gordon, Stuart C ^b   Kaplan, Marshall M ^c   Koff, Raymond S ^d   Regenstein, Frederic ^e   Everson, Gregory ^f   Lee, Young Mee ^c   Weiner, Francis ^a   Silverman, Ann ^b   Plasse, Terry ^g   Fedorczyk, Dave ^g   Liao, Mei June ^g  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d METROWEST MEDICAL CENTER   (United States)

^e OCHSNER CLINIC FOUNDATION   (United States)

^f UNIVERSITY OF COLORADO HOSPITAL   (United States)

^g Interferon Sciences   (United States)

^h JACOBI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHAN3 INTERFERON;

ARTICLE; ASCITES; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GENOTYPE; GRANULOCYTOPENIA; HEPATITIS C; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION; THYROID DISEASE;

EID: 12644274686     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510250232     Document Type: Article

References (43)

1. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull 1990;46:423-441.
2. Miyamura T, Saito I, Katayama T, Kituchi S, Tateda A, Houghton M, Choo Q-L, et al. Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus DNA: application to diagnosis and blood screening posttransfusion hepatitis. Proc Natl Acad Sci U S A 1990;87:893-897.
3. Morb Mortal Wkly Rep 1991;40:1-25.
4. Alter MJ, Sampliner RE. Hepatitis C: miles to go before we sleep. N Engl J Med 1989;321:1538-1540.
5. Alter HJ. Chronic sequences of non-A, non-B hepatitis. In: Seeff LB, Lewis JH, eds. Current Perspectives in Hepatology. New York: Plenum, 1989: 83-97.
6. Dienstag JL. Non-A, non-B hepatitis. Recognition, epidemiology and clinical features. Gastroenterology 1983;85:439-462.
7. Wejstal R, Lindberg K, Lundin P, Norkrans G. Chronic non-A, non-B hepatitis: a long term follow-up study of 49 patients. Scan J Gastroenterol 1987;22:1115-1121.
8. Hopf U, Moller B, Kuther D, Stemerociwz R, Lobeck H, Ludtke-Handjery A, Walter E, et al. Long term follow-up of posttransfusion hepatitis and frequency of circulation antibodies to hepatitis C virus. J Hepatol 1990; 10:69-76.
9. Tremolda R, Casarin C, Alberti A. Long term follow-up of non-A, non-B (type C) posttransfusional hepatitis. J Hepatol 1992;16:273-281.
10. Alter HJ, Hoofnagle JH. Non-A, non-B: observations of the first decade. In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral Hepatitis and Liver Disease. Orlando: Grune & Stratton, 1984:354-354.
11. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, et al. Treatment of chronic non-A, non-B hepatitis with recombinant alpha interferon. N Engl J Med 1986;315:1575-1578.
12. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
13. DiBisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
14. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AN, Degos F, Coppere H, et al. Recombinant human a interferon in patients with chronic hepatitis non-A, non-B hepatitis: a multicenter randomized controlled trial from France. HEPATOLOGY 1991;13:393-397.
15. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, et al. A comparison of three doses of interferon alfa-2b regimens for the long term treatment of chronic hepatitis non-A, non-B hepatitis. N Engl J Med 1995;332:1457-1462.
16. Marcellin P, Pouteau M, Martinot-Pignoux M, Degos F, Duchatelle V, Boyer N, Degott C, et al. Lack of benefits of escalating dosage on interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995;109:156-165.
17. Kobayashi Y, Watanabe S, Konishi M, Yoko M, Katehashi R, Kaito M, Kondo M, et al. Quantification and typing of serum hepatitis C RNA in patients with chronic hepatitis C treated with interferon. HEPATOLOGY 1993;18:1319-1325.
18. Castilla A, Camps J, Civira MP, Prieto J. Lymphoblastoid a-interferon for chronic hepatitis C: a randomized controlled study. Amer J Gastroenterology 1993;88:233-239.
19. Camps J, Castilla A, Ruiz J, Civira MP, Prieto J. Randomized trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol 1993;17:390-396.
20. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. HEPATOLOGY 1995;22:700-706.
21. Tong MJ, Blatt LM, Resser K, Klein M, Figuero T. Treatment of patients with chronic HCV infection with a novel type-1 interferon, consensus interferon [Abstract]. HEPATOLOGY 1993;18:A150.
22. Diaz MO, Bohlander S, Allen G. Nomenclature of the human interferon genes. J Interferon Res 1993;13:61-62.
23. Fleshner PR, Freilich MI. Adjuvant interferon for anal condyloma. A prospective, randomized trial. Dis Colon Rectum 1994;37:1255-1259.
24. Liao MJ, Axelrod HR, Kuchler M, Yip YK, Kirkbright E, Testa D. Absence of neutralizing antibodies to interferon in condyloma acuminata and cancer patients treated with natural human leukocyte interferon. J Infect Dis 1992;165:757-760.
25. Zhao XX, Hua J, Kuchler M, Testa D, Liao MJ. Absence of neutralizing antibody development in patients treated with interferon alfa-n3. [Abstract] J Interferon Cytokine Res 1995;15(Suppl):141S.
26. Shrestha R, McKinley C, Bilir BM, Everson GT. Possible idiopathic thrombocytopenia purpura associated with natural alpha interferon therapy for chronic hepatitis C infection. Am J Gastroenterology 1995;90:1146-1147.
27. Petka S, Langer JA, Zoom KC, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987;56:727-777.
28. Fan SX, Skillman DR, Liao MJ, Testa D, Meltzer MS. Increased efficacy of human natural interferon α(IFN-α n3) versus human recombinant IFN-α 2 for inhibition of HIV-1 replication in primary human monocytes. AIDS Res Hum Retroviruses 1993;9:1115-1122.
29. Jouet P, Thoraval-Roudot F, Dhumeaux D, Metreau JM. Comparative efficacy of interferon alfa in cirrhotic and non-cirrhotic patients with non-A, non-B C hepatitis. Gastroenterology 1994;106:686-690.
30. Reichard O, Faubourg U, Ryden A, Matson L, Norkrans, Sonnenberg A, Wejstal R, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with recombinant interferon α 2b for 60 weeks. HEPATOLOGY 1994;19:280-285.
31. Gretch DR, Road C, Carither RLL, Wilson RA, Williams B, Carey L. Assessment of hepatitis C viremia using molecular amplification technologies: correlation and clinical implications. Ann Intern Med 1995;123:321-329.
32. Castillo I, Bartolome J, Navas S, Gonzales S, Hairier M, Careen V. Virological and long term follow-up of patients with chronic hepatitis C treated with interferon. HEPATOLOGY 1994;19:1342-1346.
33. Gurakar A, Foggily S, Ferric H, Maria N, Balkan M, Van Thiel D, Friedlander L. Utility of hepatitis C virus determination as an end point for interferon treatment of chronic hepatitis C. HEPATOLOGY 1995;22:1109-1112.
34. Negro F, Bald M, Mondardini A, Landry G, Canad M, Mansion P, Abate ML, et al. Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. Gastroenterology 1994;107:479-485.
35. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, et al. A randomized trial comparing three different regimens of alpha-2a interferon in chronic hepatitis C. HEPATOLOGY 1995;22:700-706.
36. Picciotto A, Callea F, Varagona G, Bardellini E, Borzone S, De Conca V, Vallarino E, et al. Lymphoblastoid interferon therapy in chronic hepatitis C: biochemical, virological and histological evaluation of two different doses. Liver 1995;15:20-24.
37. Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, Seizaburo K. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterology 1994;89:2151-2155.
38. Saito T, Shinzawa H, Kuboki M, Ishibashi M, Toda H, Okuyama Y, Nakamura T, et al. A randomized, controlled trial of human lymphoblastoid interferon in patients with compensated cirrhosis. Am J Gastroenterology 1994;89:681-686.
39. Terrault N, Wright T. Interferon and hepatitis C. N Engl J Med 1995;332: 1509-1511.
40. Roffi L, Mels CG, Antonelli G, Bellati G, Panizzuti F, Piperno A, Pozzi M, et al. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology and management. HEPATOLOGY 1995;21:645-649.
41. Bonetti P, Diodati G, Casarin C, Scaccaborozzi S, Realdi G, Ruol A, Alberti A. Interferon antibodies in patients with chronic hepatitis C virus infection treated with recombinant interferon alpha-2a. J Hepatol 1994;20:416-420.
42. Coonjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of sustained beneficial response to interferon alfa therapy in chronic hepatitis C. HEPATOLOGY 1995;22:1326-1329.
43. Martinot-Peignoux M, Marcellin P, Pouteau C, Castelnau C, Boyer N, Poliquin M, Degott C, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. HEPATOLOGY 1995;22:1050-1056.